Study highlights lack of access to right antibiotics in eight countries
Only 7.8% of patients with drug-resistant infections in India received an appropriate antibiotic, a study of eight nations published in The Lancet Infectious Diseases journal has revealed. Lack of access to appropriate treatment for such serious infections increases morbidity and mortality, besides driving up health care costs and prolonging hospitalisation.
Research carried out by Global Antibiotic Research and Development Partnership (GARDP), a non-profit health organisation, has revealed that a significant number of multidrug-resistant infections in low- and middle-income countries (LMICs), including India, are not being treated appropriately, because of large gaps in access.
The study looked at which antibiotics were available to treat nearly 1.5 million cases of carbapenem-resistant Gram-negative (CRGN) infections across eight geographically diverse and populous LMICs — Bangladesh, Brazil, Egypt, India, Kenya, Mexico, Pakistan and South Africa. India's 7.8% measures are against an average of 6.9% across all eight countries.
The study was undertaken to establish the barriers along the treatment pathway from initial presentation at the health facility to laboratory diagnostic testing to antibiotic access.
Two key parameters
The researchers defined and estimated two key parameters — the need for treatment or total number of resistant bacterial infections; the number of individuals potentially initiated on appropriate treatment, specifically focusing on CRGN infections. Researchers used The Lancet's 'Global Burden of Antimicrobial Resistance' (GRAM) study and IQVIA data for 2019 to arrive at the numbers.
'We were looking at three aspects,' explains Jennifer Cohn, GARDP's Global Access Director and senior author of the study. 'These were: To evaluate the access to antibiotics gap; create better data that will be an imperative to better define the cascade of care; and look at strong programmes or innovations that enabled better antibiotics stewardship in nations.' While the study only focused on eight countries, including India, she said there was a good reason to believe that the findings from this study also apply to other LMICs.
'We all know that high-end antibiotics are extensively overused and misused in countries like India, contributing significantly to resistance against these life-saving drugs. But this paper reminds us of an equally alarming issue — lack of access to these same antibiotics,' says Abdul Ghafur, infectious diseases specialist and founder, AMR Declaration Trust.
'In 2019, India had nearly 10 lakh carbapenem-resistant gram-negative infections, yet less than 1 lakh patients received appropriate treatment. The modelling suggests that around 3.5 lakh deaths occurred due to these infections. So we are caught in a paradox — irrational overuse on one end, and insufficient access on the other,' he added.
'To address this dual crisis, we must act on both fronts: preserve existing antibiotics through responsible use and ensure access to those who genuinely need them,' Dr. Ghafur further suggested. In the paper, authored by Anant Mishra et al, the recommendations are to set in place regulatory guardrails that will not only control antibiotics use, but also make sure that the access gap is bridged by nations and institutions. They also call for more research to better understand the barriers in accessing care, diagnoses and appropriate treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
New tools offer breakthrough in tackling 'hidden hunger' in India
NEW DELHI: A new toolkit developed by The George Institute for Global Health (GIGH), India, in collaboration with Rutgers University, US and other international partners, promises to reshape India's response to malnutrition by helping map and understand its complex food environments. Tired of too many ads? go ad free now The study, published in Current Developments in Nutrition, addresses how availability, affordability, and access to food influence nutritional outcomes in low- and middle-income countries (LMICs) like India. The GIGH is an independent medical research organisation with a focus on improving the health of millions worldwide, particularly those living in disadvantaged settings. Established in 1999 and headquartered in Sydney, it operates major research centres in India, China, and the UK. Led by Shauna Downs of Rutgers and featuring Suparna Ghosh-Jerath from The George Institute, the research introduces a 'Food Environment Toolbox' that includes seven practical tools such as participatory mapping and market assessments. These tools were piloted across rural, urban, and peri-urban areas in India and Cambodia. India's food landscape is shifting rapidly, with growing market dependence not matched by better nutrition. 'We developed the toolbox through an iterative process, ensuring it reflects the realities of LMICs,' said Dr. Ghosh-Jerath. The country continues to battle a double burden—widespread nutrient deficiencies alongside rising diet-related diseases. National surveys reveal severe anaemia among women and children, underscoring the need for diet quality over mere calorie sufficiency. The new toolkit could enhance key nutrition schemes like POSHAN Abhiyaan, ICDS, and the Mid-Day Meal Scheme by aligning them more closely with regional food realities. 'The tools were adaptable across diverse contexts,' noted Dr. Downs, calling them a 'timely step toward more effective, evidence-based nutrition policy.'
India Today
4 days ago
- India Today
Superbugs are spreading as India faces gaps in drug supply, access to treatment
While antibiotics are being overused in some places, leading to the rise of deadly superbugs, in other parts of the world, people are dying because they can't access these life-saving drugs at all.A study, published in The Lancet Infectious Diseases, was led by the Global Antibiotic Research and Development Partnership (GARDP), a non-profit that works to improve access to antibiotics, looked at nearly 1.5 million cases of infections caused by carbapenem-resistant Gram-negative (CRGN) bacteria across eight low- and middle-income countries, including India, Brazil, and South bacteria are dangerous because they are resistant to "last-line" antibiotics. These are medicines that are used when all others fail. Yet, the study found that only 6.9% of patients in these countries received the right CARRIES THE HEAVIEST BURDENIndia had the largest number of cases among all countries studied. It also procured 80% of the full antibiotic courses examined. But despite this, only 7.8% of people with CRGN infections received the proper points to a gap between drug supply and actual access to treatment.A full course of antibiotics means the complete number of doses a patient must take to fully fight off an infection. The study found that only 6.9% of patients in 8 countries, including India, received the right treatment. () advertisementMissing out on even a part of this treatment makes it less effective and more dangerous in the long drug-resistant bacteria are commonly found in water, food, the environment, and even in our own bodies. They can cause serious infections like urinary tract infections (UTIs), pneumonia, and food babies, elderly people, and hospital patients are especially at risk, particularly those in intensive care units (ICUs).CRGN infections are tough to treat because the bacteria no longer responds to some of the most powerful antibiotics we have. This is where the crisis deepens: in places where these infections are rising, the drugs needed to treat them are either missing or too ACCESS CRISISFor years, the focus has been on the overuse of to Dr. Jennifer Cohn, GARDP's Global Access Director, the reality is that many people in low- and middle-income countries with deadly drug-resistant infections are "dying because they can't get the antibiotics they need," she was quoted by study looked at eight different intravenous antibiotics that are active against these resistant bacteria. Bacterial infections are tough to treat because the bacteriano longer responds to some of the most powerful antibiotics we have. () Tigecycline, one of the drugs in the study, was the most widely used. But even then, only about 1 lakh full courses were available across all eight countries, far fewer than the 1.5 million people who needed ARE PATIENTS MISSING OUT?As per the study, there are many reasons why patients don't receive the right could be because they aren't reaching the right hospital or clinic, not getting an accurate diagnosis, not able to access the correct antibiotics or there's a high cost of newer of these antibiotics are simply too expensive for the average patient in countries like India. Without better policies, price regulation, and access programs, millions will continue to suffer or die POLICIESThe experts said that two things are needed urgently: stronger rules to prevent misuse of antibiotics and better systems to make them affordable and available to those who truly need access alone isn't enough. The world is also facing a shrinking pipeline of new fewer companies investing in antibiotic research, the options for treating future infections are has one of the highest burdens of antimicrobial resistance (AMR) in the world. But researchers say the country also holds great potential to lead the global fight against drug-resistant infections. India has one of the highest burdens of antimicrobial resistance (AMR) in the world. () India's strong pharmaceutical sector is already leading efforts in antibiotic innovation. From developing new drugs to improving diagnostics, the country has a head suggest that India can further improve by gathering local data. This would help identify what's needed, where the gaps are, and how to fix them. Some states are already trying new instance, Kerala is using a "hub-and-spoke" system where smaller clinics get support from larger hospitals in treating complex solution is pooled procurement, where hospitals or states buy drugs together in bulk, reducing costs. This has worked for cancer medicines and could be tried for antibiotics the end, the battle against superbugs is not just about using antibiotics wisely, it's also about making sure they're within everyone's Reel
Time of India
28-05-2025
- Time of India
Kin of girl who contracted HIV during blood transfusion being compensated, state govt tells Kerala high court
Kochi: The state govt has informed high court that an order has been issued sanctioning appropriate financial aid to the father of a nine-year-old girl who allegedly contracted HIV during a blood transfusion at the Regional Cancer Centre (RCC), Thiruvananthapuram, and died in 2018. Tired of too many ads? go ad free now Health and family welfare additional chief secretary Rajan Khobragade submitted in an affidavit that necessary instructions had also been issued to the revenue (disaster relief fund) department to take further steps for disbursing the financial assistance from the chief minister's disaster relief fund (CMDRF) on an urgent basis, vide order dated May 12. The affidavit was filed in response to a petition submitted by the girl's father, seeking adequate financial aid to help the family cope with the mental trauma caused by the child's untimely death and to relieve the financial burden from prolonged medical treatment. The girl, initially suspected to be suffering from leukaemia, was treated at the Medical College Hospital, Alappuzha, and later referred to RCC. She underwent 49 blood transfusions during her treatment. According to the petitioner, one of the blood donors was later found to be HIV-positive. He alleged that his daughter, who was HIV-negative at the start of treatment, contracted the infection during her treatment at RCC. However, the affidavit stated that RCC was of the considered view that the child and her family were provided full medical, psycho-social and emotional support throughout the unfortunate episode and that no lapses could be attributed to the RCC. The RCC had not recommended compensation, contending that the cause of death was not HIV infection. It was also submitted that RCC does not maintain any funds for compensating deaths or accidents arising from contingent events linked to the institution. Tired of too many ads? go ad free now The affidavit also included technical details regarding the current blood testing equipment used at RCC, highlighting the advancements in technology, including the make, model, and its superiority over the equipment in use at the relevant time.
